Interprandial blood glucose homeostasis is maintained by endogeneous hepatic and renal glucose production via glycogenolysis and gluconeogenesis. In the final step of both pathways, intracellular glucose-6-phosphate (G6P) is transported into the endoplasmic reticulum (ER) where it is hydrolyzed to glucose by glucose-6-phosphatase (G6Pase, now renamed as G6Pase-α), which embedded in ER membrane. Unlike G6Pase-α which is expressed only in the liver, kidney, and intestine, a second G6Pase isoform, G6Pase-β (previously known as UGRP, ubiquitously expressed G6Pase catalytic subunit-related protein), has been recently identified, which is expressed ubiquitously with a high expression amount in skeleton muscle, kidney, heart, brain and testis. Both enzymes share similar kinetics and structures and couple with the G6P transporter (G6PT) to form an active G6Pase complex. It has been shown that the N- and C- terminal end of G6Pase-α are critical for maintenances of protein stability, sorting and enzyme activity. However the same effects on G6Pase-β are still not clear. The purpose of this study was to construct serially deleted mutations at the N- and C- terminal regions of G6Pase-β and evaluate their effects on the protein stability, ER membrane sorting and G6P phosphohydrolase activity by using PCR, transient transfection, indirected- immunofluorescence staining, phosphohydrolase assays, western blotting, and semi-quantitative PCR. Here, we found that the N- terminus was more significant than the C- terminus with the reduction of protein stability and enzyme activity. Nevertheless, it seemed no difference on their ER membrane sublocalization. Furthermore, we showed that degradation of both wild-type and mutant G6Pase-β was inhibited by lactacystin, a potent proteasome inhibitor. Base on this study, we should further understand the molecular basis of G6Pase family, especially G6Pase-β.